Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miltefosine plus pentoxifylline for mucosal and cutaneous leishmaniasis in Brazil
RBR-72dv9nPhase 3Recruiting
- Sponsor
- University of Brasília
- Start
- Sep 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of miltefosine, pentoxifylline and meglumine antimoniate in mucocutaneous leishmaniasis (MCL) and cutaneous leishmaniasis (CL) (4 arms), sponsored by University of Brasília. Started Sep 2015; status: recruiting.
02
Drugs
miltefosinepentoxifyllinemeglumine antimoniate
03
Conditions
mucocutaneous leishmaniasis (MCL)cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on RBR-72dv9n.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-72dv9n.